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1. Introduction
Drug repurposing (also known as drug repositioning, drug repro-
filing, indication expansion or indication shift) involves establish-
ing new medical uses for already known drugs, including
approved, discontinued, shelved and experimental drugs.
Although this strategy is far from new, it has gained considerable
momentum in the last decade: about one-third of the approvals
in recent years correspond to drug repurposing, and repurposed
drugs currently generate around 25% of the annual revenue for
the pharmaceutical industry [1]. Unsurprisingly, the strategy has
thus been integrated in the life cycle management of pharma-
ceutical products. Public and non-for-profit organizations have
released specific programs to promote drug repurposing initia-
tives (see, for instance, the successful Discovering New
Therapeutic Uses for Existing Molecules initiative launched by the
NIH–National Center for Advancing Translational Sciences in
partnership with several pharmaceutical companies [2]).
Moreover, a myriad of small, drug repurposing-focused compa-
nies have been created in the last 20 years [1,3]. The increasing
interest in drug repurposing can be also realized in the evolution
of related academic publications (Figure 1).
Since the new indication is built on previous knowledge, such
as pharmacokinetic and manufacturing data, the drug develop-
ment timeline is substantially shortened, as is the required
investment. The main advantage of repurposed candidates is
that it many cases they have already proven to be sufficiently
safe in preclinical models and, at least, at early-stage trials in
humans, thus being less likely to fail from a safety point of view in
subsequent efficacy trials (unless drug–disease interactions are
found). In the case of approved drugs, they have successfully
passed clinical trials and regulatory scrutiny, and they have
already undergone post-marketing surveillance.
In principle, if dose compatibility is found (i.e. the required
strength for the new indication is equal or lower than the one
used for the original indication) [4], much of the preclinical
testing, safety assessment, and even phase I clinical trials
might be bypassed, as only efficacy for the new indication
should be now confirmed at preclinical and clinical levels.
Most of the successful and best-known drug repurposing
stories (e.g. sildenafil, minoxidil, aspirin, valproic acid) have
emerged, if not from serendipitous observations, from unor-
ganized (‘field’) discovery processes, often relying on the
already known pharmacology of a drug (e.g. an off-target
adverse effect) to solve a clinical problem from another
domain [5,6]. In recent years, though, the drug discovery
community has committed to the implementation of orga-
nized, systematic, data-driven drug repurposing approaches,
which in most cases integrate computational assistance [5,7,8].
Among them, we may mention signature matching of tran-
scriptomic or proteomic data; molecular similarity approxima-
tions; structure-based virtual screens and; systematic analysis
of electronic health records and clinical trial and post-
marketing surveillance data.
Here, we will briefly cover what, from our perspective, are
the most significant challenges and opportunities in drug
repurposing.
2. Drug repurposing challenges
2.1. Intellectual property and economic considerations
There are some legal aspects that could impair patenting a new
medical use and/or the enforcement of patent rights, thus dimin-
ishing the incentives for drug repurposing. First, some national
legislations impede obtaining a patent for second or further med-
ical uses (although, it is possible to protect a repurposed medical
use in most of the major pharmaceutical markets). Second, many
potential repurposing uses have already been reported in the
specialized literature or are already being exploited in the clinical
practice as off-label, non-registered uses [8]. Even if such uses have
still not been endorsed by controlled clinical trials, the information
is already in the public domain and affects novelty and, conse-
quently, patentability.
For drugs that are off-patent, a patent for the new indication
can be obtained but enforceability could become an issue if the
new indication makes use of already available strengths and
dosage forms. Therefore, whereas using the same strengths
than were marketed for the original indication might be useful
to exploit some of the advantages of drug repurposing, an ideal
situation would be than the new indication required non-
marketed strengths (preferably, lower than the previously
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available ones) or that it required a unique, new formulation
[8,9]. Newer derivatives are not a valid option here, since chan-
ging the drug molecule implies stepping away from the repur-
posing strategy.
Regarding exclusivity, the European Union usually provides
8 years of data protection plus 2 years of market exclusivity; if
a second indication is developed by the originator during the
8-year data exclusivity period, an additional year of protection
may be granted; on their part, the United States grants an
initial period of 5 years which might be expanded by 3 years
for a new use [10]. Nevertheless, such extra periods might not
constitute an appropriate time to make an acceptable return
of investment, with additional economic incentives being
required to make drug repurposing cost-effective.
2.2. Data and compound availability
Whereas the open-source model is progressively gaining
ground within the drug discovery community [11], public
access to certain types of (valuable) data (e.g. clinical trials) is
still limited. Even if accessibility was not an issue, some types
of data are less friendly to data mining, integration and manip-
ulation (e.g. imaging data) or are sometimes offered in a non-
standardized manner [8]. Integrating different types of data
has also proven computationally demanding as it increases
the power of analysis [12].
Despite a shelved drug could be regarded as an idle capital
or a missed or postposed opportunity, some pharmaceutical
companies are less inclined than others to release their che-
mical libraries (e.g. failed drugs) to branch the possible appli-
cations of their compound collections (or could prove
extremely selective at choosing partners), which could pose
a fundamental barrier to drug repurposing prospects if
a potential repurposed indication falls outside the organiza-
tion’s core disease area.
Even when a big company is willing to engage in crowd-
sourcing/collaborative efforts with smaller players (e.g. bou-
tique firms or academic groups) it is imperative to facilitate
and make more flexible the inherent administrative proce-
dures, especially at the level of material transfer agreement
signatories and compound distribution.
Compound availability with generic active pharmaceutical
ingredients might occasionally also present some issues, espe-
cially if the compound is gone from the international market.
Finding a reliable vendor in such circumstances might prove
challenging.
2.3. Can the repurposing space be exhausted?
Despite the universe of diseases requiring improved therapeu-
tic solutions (or, plainly, therapeutic solutions) is undoubtedly
large, it may be argued that systematic drug repurposing
campaigns may rapidly exhaust the drug repurposing pro-
spects for a given disease (after all, the number of repurposing
candidates is limited and it expands rather slowly year
after year).
For example, several high-throughput screens directed to
the identification of trypanocidal repurposed drugs with pos-
sible applications as treatments for Chagas disease have been
reported throughout the years (see, for example, refs [13–16]),
and this without taking into consideration previous low-
throughput screens [17,18] and in silico screens or wet screens
focused on specific drug targets and comprising experimental
validation of the hits (see, for instance, refs [19,20]). A valid
Figure 1. Number of scopus-indexed publications containing the terms ‘drug’ and ‘repurposing’ or ‘drug’ and ‘repositioning’ in their title, abstract or keywords,
versus year of publication. 3.3k publications were retrieved (left). Distribution of the publication types (right). 68% of the retrieved documents correspond to original
articles.
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question that emerges is how many more repurposed-
oriented phenotypic screens focused on Trypanosoma cruzi
would be justified. By the same token, we could ask if enthu-
siasm in drug repurposing would decay gradually as succes-
sive systematic screens on collections of known drugs are
executed.
An immediate answer would be that the strategy could be
redirected to unexplored target disorders. The possibilities of
drug repurposing may be amplified if instead of potential
repurposed monotherapies, drug combinations are examined,
a strategy that is already bearing fruit in the field of infectious
diseases, as exemplified by the approval of nifurtimox–eflor-
nithine combination therapy for second-stage African trypa-
nosomiasis [21]. Precision and system medicine, each in its
own way, also offers a whole new prospect to expand the
scope of drug repurposing, as discussed in the next sections.
At last, target-oriented screensmay hold additional value. Once
an approved drug has proven its activity on an unsuspected
target, the whole set of compounds from a pharmaceutical firm
that share the same active scaffold could be explored (typically,
hundreds of such compounds are generated and used to build
structure–activity relationships during hit-to-lead and lead-
optimization programs; the lead compound for one therapeutic
goal might not necessarily be the same for another condition).
3. Drug repurposing opportunities
3.1. Rare and neglected conditions
Drug repurposing is a particularly attractive approach for rare
and neglected conditions, where the economics for developing
a drug are unfavorable, explaining why academics and non-for-
profit organizations have a predominant role in the drug discov-
ery process for those diseases, and why specific regulatory mea-
sures and public policies encourage research into these types of
disorders. Such measures include tax waiving, fast-track
approval, grants and regulatory fee waivers [8]. Noteworthy,
a considerable fraction of the Drug for Neglected Diseases initia-
tive (DNDi)’s portfolio undergoing clinical trials corresponds to
repurposed drugs, including fexinidazole, fosravuconazole,
Ambisome™, and miltefosine. In fact, fexinidazole is the first oral-
only drug, with the potential for treating advanced-stage sleep-
ing sickness, approved in 30 years [22], and DNDi spent only USD
62.5 million in its development, in contrast with the estimated 1
to 3 billion dollars for a de novo drug. Interestingly, some of the
commercial barriers to drug repurposing (concerns regarding
off-patent drugs) are not as important when addressing
neglected conditions, since investigations of therapeutic solu-
tions for such disorders are not driven by profit expectancies.
What is more, repurposing a low-cost, off-patent drug might
even be desired to assure accessibility.
In the case of rare diseases, whose pathophysiology is often
poorly characterized, computational techniques for predictive
repurposing offer a quick way of identifying testable hypoth-
eses that may be translated into the clinic, with large-scale
genome-sequencing initiatives contributing to identify the
genetic variation/s responsible for the disorder, and opening
up opportunities to rapidly repurpose drugs that target the
correspondent protein/s [8].
3.2. Precision medicine
Precision medicine is an emerging approach that considers
individual variability in genes, environment, and lifestyle for
each person to decide on or pursue an appropriate treatment
[23]. It is increasingly clear that some disorders with common
traits that in the past were characterized as a single condition
actually comprise a spectrum of diseases and that more effec-
tive and/or safe medications could be found if tailored to
variations in an individual’s genome, transcriptome, proteome,
and metabolome, or to specific types of a general condition.
The positive outcome of such approaches is already being
realized in the field of oncology. For instance, a recent case
report on a patient with metastatic colorectal cancer, treat-
ment-related toxicity, and resistance to chemotherapy and
radiation [24] seems particularly relevant in relation to drug
repurposing. The patient underwent immunohistochemical
analysis for expression of the MMR proteins MSH2, MSH6,
PMS2, and MLH1 and the V600E mutant BRAF protein. Whole-
genome sequencing was carried out on the pretreatment
tumor and blood, and whole-genome sequencing and whole
transcriptome sequencing were performed on the metastatic
tumor. Whole-genome sequencing identified more than 2000
genomic alterations, including point mutations, insertions,
deletions, and copy-number variations. Among the most dif-
ferentially expressed genes identified through transcriptome
analysis, there were the members of two proto-oncogene
families, FOS and JUN. These data supported that blocking
the renin–angiotensin system could provide therapeutic ben-
efit, which led to the (hard) repurposing of the antihyperten-
sive angiotensin II receptor antagonist irbesartan as an
anticancer therapy, resulting in the patient experiencing
a radical and persistent response.
3.3. Systems medicine
Systems medicine/network pharmacology offers an integrative
perspective on previous (and seemingly colliding) paradigms
in drug discovery: phenotypic-oriented and target-oriented,
‘rational’ drug discovery. Network and metabolic control ana-
lysis can be useful tools to design multi-target therapeutics or,
alternatively, choose a synergistic drug combination. For
instance, nifurtimox–eflornithine combination therapy has
been included in World Health Organization’s Model List of
Essential Medicines to manage advanced stages of the
Gambiense form of sleeping sickness. The combination is
easier to administer, it has a shorter treatment duration than
the eflornithine monotherapy, and it is potentially protective
against the emergence of resistant parasites. Interestingly,
both drugs in the exemplified combination are repurposed
cases: eflornithine was initially developed for cancer treatment
in the late 1970s, and nifurtimox was originally approved for
the treatment of American trypanosomiasis.
Combination drug repurposing can expand the horizon of
drug repurposing, which has so far mostly explored repurpos-
ing known drugs as monotherapies: naturally, the combina-
tory nature of polypharmacy turns the space of potential
combination drug repurposing much more difficult to exhaust
than that of single-drug therapies.
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Furthermore, many newly identified active compounds
have low potency, which limits their immediate clinical appli-
cations because the tolerated plasma drug concentrations are
lower than the effective ones. Synergistic drug combinations
are an alternative approach to increase the success rate of
drug repositioning, as they may lower the required therapeu-
tic doses in comparison with monotherapies [25].
3.4. Collaborative models
There is increasing realization that pharmaceutical companies
and academics can contribute in a highly complementary man-
ner to the discovery of novel repurposing prospects.
Pharmaceutical companies have highly valuable (though often
idle) chemical libraries of failed or shelved drug candidates, and
they have a first-hand experience on translational research and
clinical development. Furthermore, they can provide access to
screening technologies that are difficult to acquire and maintain
for most of academic institutions. Biotechnology companies and
academics possess valuable knowledge on emerging areas of
disease biology, which may lay the foundation for highly inno-
vative medications. Non-negligible byproducts of such type of
collaborations include human capacity development and
exchange [11]. From an intellectual property perspective, some
options that can be explored include patent pools, open licen-
sing for drug development targeting neglected or rare diseases
and allowing participation of academic institutions and staff into
the patent ownership for new medical uses. New collaboration
and business models are arising to bridge stakeholders, includ-
ing new funding models that welcome venture capitals, public
funding, and non-for-profit organizations. Such models might
greatly impact in certain fields of medicine (e.g. rare disorders)
where drug repurposing plays a prominent role.
4. Expert opinion
The relevance of drug repurposing in the pharmaceutical sector
has been progressively growing in the recent years, with about
one-third of approvals corresponding to repurposed drugs,
some of which have even achieved blockbuster status.
The successful drug repurposing stories have paved the
way for new models of collaboration between the public
and private sectors, a virtuous partnership which, in our
opinion, is far from having reached its highest point yet.
Government agencies and organizations have the tools to
elaborate solutions to overcome some of the legal and
commercial barriers faced by drug repurposing projects. On
their part, pharmaceutical companies have the invaluable
(though sometimes idle or underexploited) capital of their
proprietary chemical libraries, including failed and shelved
drug candidates which may be rescued to address unmet
medical needs (prominently, rare and neglected conditions).
Moreover, pharmaceutical sponsors and government agen-
cies and other stakeholders also possess access to restricted,
crucial information emerging from clinical trials, which may
imply a quality leap for the drug discovery community if
allowed into the public domain. Possibly, open collaboration
models bridging academy with private partners (non-for-
profit organizations and industry) will continue to grow, as
drug rescue poses excellent, cost-efficient opportunities to
commercially exploit abandoned drug projects and maxi-
mize the benefits of pharmaceutical companies’ portfolios.
Once and again, drug repurposing has been advocated as an
interesting strategy to explore new pharmaceutical solutions for
rare and neglected conditions (in fact, many of the available
medications for such conditions can be regarded as repurposed
drugs). The pursue of pharmaceutical solutions for rare and
neglected disorders, whereas maybe not particularly profitable
in purely economic terms, does imply other forms of value, such
as corporate social responsibility and the consequent increased
social awareness/perception of pharmaceutical companies.
Social responsibility involves sustaining the equilibrium
between economic development and the welfare of the society
and environment; one of its goals is, thus, helping to eliminate
or reduce barriers such as financial condition. Government orga-
nizations, on their part, also have the means to promote such
initiatives though different economical incentives: it is, then,
essential to gain and generate awareness that economic loss
due to rare and neglected conditions greatly exceeds the
required investment to develop new therapeutic solutions.
Systems and precision medicine are possibly the two fields
that show greater prospects for drug repurposing.
Network pharmacology underlines the possible advan-
tages of polypharmacology to treat complex disorders. The
paradigm is also showing promise in the field of infectious
diseases. In complement with metabolic control analysis, this
holistic approach to drug discovery allows a rational choice
of drug target combinations and, therefore, of repurposed
drug combinations. Often, hits emerging from systematic
screens are only moderately potent (usually, in the low
micromolar or sub-micromolar range), which, in the case of
drug repurposing, greatly limits the perspectives for repur-
posed drug candidates: whereas de novo drug discovery can
exploit hit-to-lead and lead optimization programs to gain
potency and balance pharmaceutically desirable properties,
repurposed candidates, by definition, cannot be optimized
without losing the repurposing advantages. Synergistic drug
combinations of repurposed drugs offer a way to exploit
moderately potent repurposed hits for new indications.
On the other hand, as precision medicine will deepen the
characterization, understanding, and classification of disease
(e.g. uncovering disease subtypes) new drug repurposing pro-
spects will be uncovered, revitalizing the field.
In parallel, technological advances are required to effi-
ciently extract and integrate heterogeneous large-scale data,
such as imaging and structural data or clinical trial documen-
tation, electronic health records, etc.
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